Polaryx Therapeutics PLYX Institutional Ownership

Updated Oct 10, 2026

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) was held by 13 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Their combined stake equaled 4.40% of outstanding shares in Q2 2026, down from 4.79% in Q1 2026.
• Total holdings of PLYX shares fell 3.27% from Q1 2026.
• Of the 13 holders of PLYX in Q2 2026, 7 added to their positions, 2 reduced their stakes and 4 left their positions unchanged.
• The aggregate institutional position in Polaryx Therapeutics was 2.19Mn shares at the end of Q2 2026, down 74.04K from the prior quarter.
• Vanguard Capital Management LLC held the largest position in PLYX at 1.66Mn shares as of June 30, 2026, or 3.33% of shares outstanding.
• The biggest increases in PLYX positions during Q2 2026 came from Tower Research Capital LLC (+1.22K shares), Vanguard Fiduciary Trust Co (+516 shares) and Geode Capital Management, LLC (+325 shares).
• Among holders that kept a stake in Polaryx Therapeutics, the biggest sellers in Q2 2026 were UBS Group AG (-12.2K shares) and Vanguard Capital Management LLC (-516 shares).
• Polaryx Therapeutics' 10 largest institutional shareholders as of Q2 2026 were Vanguard Capital Management LLC (1.66Mn shares), Geode Capital Management, LLC (171K shares), Vanguard Fiduciary Trust Co (105.07K shares), HRT Financial LP (82.09K shares), State Street Corp (58.1K shares), BlackRock, Inc. (41.01K shares), Jane Street Group, LLC (31.44K shares), Northern Trust Corp (27.99K shares), Allworth Financial LP (7.73K shares) and Vanguard Global Advisers, LLC (6.32K shares), per Business Quant data.